Protagonist Therapeutics, Inc. (PTGX)

Protagonist Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-130.15	275.19	-78.96	-127.39	-125.55
Depreciation & Amortization	1.28	0.83	0.98	1.03	0.81
Stock-Based Compensation	45.97	37.55	29.29	24.2	16.4
Other Adjustments	-5.64	-6.81	-2.04	1.79	3.79
Change in Receivables	164.88	-155	-9.99	4.24	-0.92
Changes in Accounts Payable	3.72	0.84	-2.93	1.22	-3.22
Changes in Accrued Expenses	4.58	4.29	-5.6	-12.72	19.1
Changes in Income Taxes Payable	-2.69	2.69	-	-	-
Changes in Unearned Revenue	-21.02	30.57	-	-1.6	-12.88
Changes in Other Operating Activities	-3.26	-5.99	-0.99	1.09	-5.4
Operating Cash Flow	57.67	184.15	-70.24	-108.14	-107.87
Operating Cash Flow Growth	-68.68%	-	-	-	-
Capital Expenditures	-1.59	-1.36	-0.61	-0.8	-1.1
Purchases of Investments	-546.59	-621.7	-191.05	-214.87	-286.59
Proceeds from Sale of Investments	498.84	323.57	152.4	307.14	271.83
Investing Cash Flow	-49.33	-299.48	-39.26	91.47	-15.86
Issuance of Common Stock	23.34	26.45	171.25	19	130.11
Repurchase of Common Stock	-0.48	-0.6	-0.77	-0.19	-0.19
Net Common Stock Issued (Repurchased)	22.86	25.85	170.48	18.81	129.92
Other Financing Activities	-	-	-	0.03	-
Financing Cash Flow	22.86	25.85	170.48	18.84	129.92
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-	-	-	-0.09	-0.13
Net Cash Flow	31.2	-89.48	60.98	2.08	6.07
Free Cash Flow	56.08	182.8	-70.85	-108.93	-108.97
Free Cash Flow Growth	-69.32%	-	-	-	-
FCF Margin	121.87%	42.08%	-118.08%	-409.81%	-398.31%
Free Cash Flow Per Share	0.88	2.81	-1.25	-2.22	-2.35
Levered Free Cash Flow	-149.13	307.05	-88.11	-139.16	-128.24
Unlevered Free Cash Flow	-178.13	280.89	-102.81	-143.14	-128.53

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q